Cookies for Kids’ Cancer Blog

From Good Cookie to Clinical Trial

How Your Support Has Helped Develop A New Treatment For Pediatric Cancer

Today is a good day. Today we are filled with hope. Because today marks the launch of a clinical trial for a new, less toxic treatment for children battling cancer. Days like these are so meaningful because it means that we are doing what we have set out to do, which is to empower and inspire Good Cookies all across the world to join us in raising funds and awareness for pediatric cancer research! We are very excited to announce the news of this phase 1 clinical trial with you today and to share more details of this important story over the next few months.

We sharing lots of information on our social media, through our email newsletter, and we will be posting a series of blog posts written by families with children who have battled or are still battling neuroblastoma, the deadly form of cancer that this new drug is designed to treat. We hope you stay tuned for these personal stories and are inspired to be the best Good Cookie you can be!

One Doctor, Years of Work, and HOPE at the Launch of a Clinical Trial.

It all starts with Yael P. Mossé, MD and her brilliant work at Children’s Hospital of Philadelphia (CHOP). Dr. Mossé is an attending physician at CHOP’s Cancer Center with a special interest in neuroblastoma. Her work led to a grant submission to Cookies for Kids’ Cancer in 2015, and approval by our Medical Advisory Board. It was the first grant Mossé received for this stage of pre-clinical work on the promising new drug, called Lorlatinib.

Six months after receiving the first grant from Cookies for Kids’ Cancer, Dr. Mossé’s results were moving ahead so rapidly that the NANT Consortium [New Approaches to Neuroblastoma Therapy] and the drug’s manufacturer, Pfizer, all began to merge interests to move toward the clinical trial phase. Alongside these developments came another $200,000 grant from Cookies for Kids’ Cancer to insure the testing and data were of the highest quality in hopes of benefitting children with neuroblastoma.The work has led to the launch of the trial’s enrollment process at several sites including Children’s Hospital of Philadelphia, and will become available at all 16 centers over the next several weeks.

The phase 1 study is enrolling patients at the following 16 centers:

UCSF School of Medicine    

Children’s Hospital Los Angeles

Cincinnati Children’s Hospital

Lucile Packard Children’s Hospital

Children’s Hospital Colorado

Children’s Hospital of Philadelphia

C. S. Mott Children’s Hospital

Cook Children’s Healthcare System

Hospital for Sick Children, Toronto, Canada  

Seattle Children’s Hospital      

Memorial Sloan-Kettering Cancer Center

Children’s Healthcare of Atlanta   

University of Chicago, Comer Children’s Hospital

Royal Marsden Hospital, London, England

Institut Curie, Paris, France

Children’s Hospital Boston, Dana-Farber Cancer Institute

There are so many Tough Cookies out there who could benefit from a new treatment such as this one. And although we cannot know if this first trial will lead to a second, or to a cure, we believe that this trial will serve as a source of hope for the children and families out there who are in the fight of their lives.

With your help, Cookies for Kid’s Cancer will continue funding this type of research and working alongside brilliant doctors like Dr. Mossé and respected research institutes like Children’s Hospital of Philadelphia, to develop new treatments for precious children who are battling this disease.

We will be sharing more details about this clinical trial, the story behind of how it all came together, and ways that you can help continue to fund these developments in pediatric cancer research across our social media channels so be sure to stay tuned! Facebook, Twitter, Instagram

No Comments »

No comments yet.

RSS feed for comments on this post. TrackBack URL

Leave a comment